Switchpoint Bio
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology biotech creating small molecules that target master regulatory switches in cancer.
Oncology
Technology Platform
A discovery platform focused on identifying and drugging master regulatory protein 'switchpoints' in cancer cells using small molecules.
Opportunities
Potential for breakthrough therapies if its switchpoint hypothesis yields drugs that effectively shut down core cancer survival pathways.
Risk Factors
High risk of target validation failure and the inherent difficulty of drugging complex regulatory proteins with small molecules.
Competitive Landscape
Competes with hundreds of targeted oncology biotechs; success requires identifying truly novel, druggable switchpoints not pursued by larger firms.